Privately-held UK biotech Chronos Therapeutics has appointed experienced pharma duo Fraser Murray and Timothy Schulz-Utermoehl as vice presidents of pre-clinical development.
They join Chronos from Polleo Pharma, another UK biotech start-up which they co-founded. Both have substantial scientific management expertise with big pharma companies, including Ireland-based Shire (LSE: SHP), Anglo-Swedish AstraZeneca (LSE: AZN) and Merck & Co.
The appointments follow the news that Chronos, which focuses on aging diseases, brain and central nervous system (CNS) disorders, has acquired three pre-clinical development programs from a subsidiary of Shire.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze